Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2015–2019

HaemMetabolome · Deciphering the Metabolism of Haematological Cancers

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2015-10-01 → 2019-09-30
EU contribution
€2,572,664
Participants
7
Scheme
MSCA-ITN-EJD

Lines connect the coordinator with its partners.

Results in brief

Deciphering the Metabolism of Haematological Cancers

HaemMetabolome was established to train 10 Early Stage Researchers in the fields of experimental haematological cancer research and metabolism. In the context of a Joint Doctorate scheme, each fellow was supervised and worked at two different sites. It was the objective of the project to provide research training in metabolic mechanisms associated with cancer-specific metabolic features, the characterisation of key metabolism regulators, studying the effect of drugs on specific metabolic mechanisms and the use of computational approaches to integrate different data-sets to allow predictions of drug interactions, and markers for personalised treatment. HaemMetabolome focussed on training and research using nuclear magnetic resonance (NMR) and mass spectrometry (MS) in order to understand the mechanism of metabolic regulation in haematological cancers; to link metabolic profiles to the effect of specific metabolic regulators; and to look at the effect of drugs on these cells.

Data: CORDIS, © European Union

Project objective

It has long been realised that metabolism is central to cellular development, proliferation and homeostasis. Collectively, aberrations in metabolism are now recognised as a major hallmark of cancer, opening new avenues for personalised medicine. As haematological malignancies are multi-factorial diseases, our main emphasis will be on the integration of biomedical multi-omics data and computational systems modelling with the ultimate aim to understand metabolic regulation in haematological cancers. HaemMetabolism is design to unravel the regulatory mechanisms that link cell cycle control and metabolism. For this we will screen a panel of haematological cancer cell lines for the metabolic phenotypes and against a library of inhibitors. Gene-function analyses will be performed using shRNA libraries directed against key metabolome regulators. Validation will occur in primary patient samples in vitro and in vivo in preclinical humanized niche xenograft mouse models. A systems biomedicine approach will be integrated build genome-scale transcriptional models that explain deregulated metabolic pathways relevant for the development of haematological malignancies. This work will not only open new avenues for drug discovery but will also provide a multi-disciplinary framework for student training in biomedical technologies.

Original text from CORDIS.

Participants

  • THE UNIVERSITY OF BIRMINGHAM · BirminghamCoordinatorUnited Kingdom
  • ACADEMISCH ZIEKENHUIS GRONINGEN · GroningenNetherlands
  • BRUKER BIOSPIN GMBH · EttlingenGermany
  • JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN · Frankfurt Am MainGermany
  • LIFEGLIMMER GMBH · BERLINGermany
  • TavarGenix · HeidelbergGermany
  • UNIVERSITAT DE BARCELONA · BarcelonaSpain

Links

Data: CORDIS, © European Union